Evidence map›Paper›PMID 40400212›Full record

ArticleAnnals of clinical and translational neurology2025

An Analysis for IDH-Mutant Grade 4 Astrocytoma Based on WHO CNS 5: Implication of Clinical Practice.

Xianxin Qiu, Liping Liang, Lingchao Chen, Pengjie Hong, Wanzun Lin, Jiabing Liu, Zhirui Zhou, Wenjia Zhu, Tianqi Wu, Mingyuan Pan and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical and translational neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xianxin QiuDepartment of Radiation Oncology, Huashan Hospital, Fudan University, Shanghai, China.
Liping LiangDepartment of Radiation Oncology, Huashan Hospital, Fudan University, Shanghai, China.
Lingchao ChenDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Pengjie HongDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Wanzun LinRuijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Jiabing LiuDepartment of Radiation Oncology, Huashan Hospital, Fudan University, Shanghai, China.
Zhirui ZhouDepartment of Radiation Oncology, Huashan Hospital, Fudan University, Shanghai, China.
Wenjia ZhuDepartment of Radiation Oncology, Huashan Hospital, Fudan University, Shanghai, China.
Tianqi WuDepartment of Radiation Oncology, Huashan Hospital, Fudan University, Shanghai, China.
Mingyuan PanDepartment of Radiation Oncology, Huashan Hospital, Fudan University, Shanghai, China.
Yihua ZhongDepartment of Radiation Oncology, Huashan Hospital, Fudan University, Shanghai, China.
Jing GaoShanghai Engineering Research Center of Proton and Heavy ion Radiation Therapy, Shanghai, China.
Zhiyong QinDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Yang WangDepartment of Radiation Oncology, Huashan Hospital, Fudan University, Shanghai, China.ORCID 0009-0007-5640-4994

Funding

Beijing Science And Technology Innovation Medical Development Foundation KC2023-JX-0288-BM150Science and Technology Development Fund of Shanghai Pudong New Area PKJ2021-Y48The National Natural Science Foundation of China 8240072705
6 · The paper itself

Abstract

purposeThere is ongoing debate regarding the therapeutic approach and prognosis for IDH-mutant grade 4 astrocytoma, a newly defined subtype of diffuse glioma in the 2021 WHO classification system for central nervous system tumors (WHO CNS 5). The aim of this study was to explore the clinical outcome and prognosticators for newly diagnosed IDH-mutant grade 4 astrocytoma based on our single institutional data.

methodsThis retrospective analysis included 53 consecutive patients with newly diagnosed IDH-mutant grade 4 astrocytoma, who underwent radiotherapy between September 2021 and December 2023. All patients were administered concurrent and adjuvant temozolomide. Eleven patients received adjuvant tumor-treating fields (TTFields).

resultsThe median follow-up was 15.7 months. Twenty patients had tumor relapse; three patients died, all of whom were without TTFields therapy. The median PFS for the entire cohort was 19.3 months, and the median OS was not reached. Univariate analysis indicated patients younger than 40 years (p = 0.11) or without homozygous deletion of CDKN2A/B (p = 0.11) tended to have better PFS. In addition, the TTFields group tended to have longer median PFS than the non-TTFields group in both analyses before and after propensity score matching (PSM) (24.4 vs. 18.5 months, p = 0.097, before PSM; 24.4 vs. 15.9 months, p = 0.080, after PSM). No significant independent prognostic factor was found in the multivariate analysis.

conclusionsThe study reveals important insights into clinical practice for IDH-mutant grade 4 astrocytoma. Younger age and tumor without deleted CDKN2A/B might be predictive of better outcomes. The addition of TTFields trended towards improved PFS, necessitating prospective clinical trials for further investigation.

Indexed as

AstrocytomaBrain NeoplasmsCentral Nervous System NeoplasmsIsocitrate DehydrogenaseAdultAgedFemaleHumansMaleMiddle AgedMutationNeoplasm GradingPrognosisRetrospective StudiesTemozolomideYoung AdultIsocitrate DehydrogenaseTemozolomideIDH‐mutant astrocytomaprognosisradiotherapytemozolomidetumor‐treating fields

Identifiers

PMID40400212
PMCPMC12257125

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.